Table 2.

Characteristics of the first visit with a major INSTI RAM detected.

				Timing
Timing of infection	Case	Viral load (copies/mL)	Major INSTI RAMs detected	Relative to injections	Relative to the 1st site pos visit	Days since the 1st HIV pos visit	CAB concentration (µg/mL)a
Enrollment	A2	204	E138E/K, Q148K/R	1st injection visit	Before	40	3.318
While receiving oral CAB	C1	137	Q148Q/R	8 days after the 1st injection	Before	17	1.219
	C3	102,329	E138A, Q148R	20 days after the 1st injection	Same visit	35	1.108
While receiving CAB injections	D1	130	N155H	8th injection visit	Before	0	1.613
	D2	<40	N155H	182 days after the 6th injection	Afterb	280b	0.703
	D3	<40	R263K	4th injection visit	Before	62	1.213
	D4	158	Q148R	4th injection visit	Same visitc	45	1.930

^aThe concentration of cabotegravir associated with protection against HIV infection (PAIC90) is 1.33 µg/mL.

^bIn these cases, HIV genotyping results were not obtained prior to the first site positive visit.

^cOnly three of 11 visits during this interval had a positive result with the qualitative RNA assay; two samples from this case failed genotyping.

Abbreviations: CAB, cabotegravir; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; RAM, resistance associated mutation.

Characteristics of the first visit with major INSTI RAMs detected. The first HIV positive visit was identified based on results of retrospective HIV RNA testing performed at the HPTN Laboratory Center. The first site positive visit is the first visit where the participant had a reactive rapid test or a reactive antigen/antibody test at the study site.